Slide 1: Orion Half Year Financial Report 1−6/2020
Orion Half Year Financial Report 1−6/2020
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-June 2020
Highlights in January-June 2020
Slide 4: Orion has fared well in exceptional circumstances
Orion has fared well in exceptional circumstances 1 The COVID-19 pandemic 3 increased demand for some First commercial sales of products in March-April after Nubeqa® in Japan and the EU which the demand has levelled New data from ARAMIS study off. published at ASCO. 2 With the growth of net sales al
Slide 5: COVID-19 pandemic impacts on Orion
COVID-19 pandemic impacts on Orion The most important thing is to take care of the health and safety of employees, the continuity of production and patient safety in ongoing clinical trials. The March demand spike impact Disruptions in the global supply of Gx and OTC products is chains possible but
Slide 6: Key figures 1−6/2020
Key figures 1−6/2020 Net sales Operating profit Operating profit Cash flow per share margin before financial items 572 181 32% 0.90 MEUR (493) MEUR (107) (22%) EUR (0.57) +16% +69% +56% Half Year Financial Report 1-6/2020 © Orion Corporation 17 July 2020 6
Slide 7: Development of net sales and operating profit
Development of net sales and operating profit Net sales Operating profit 35 1 1 181 22 -4 572 2 14 14 -8 9 9 31 35 493 -8 107 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mi
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-6/2020 MEUR 1-6/2020 1-6/2019 13% 250 28% +14% 9% 200 +6% 191 150 168 158 149 +7% +37% 100 +70% 95 88 17% 77 33% 50 52 56 30 Finland Scandinavia 0 Other Europe North America ROW Half Year Financial Report 1-6/2020 © Orion Corporation 17 July 2020
Slide 9: Proprietary and Specialty Products showed strong growth
Proprietary and Specialty Products showed strong growth 1−6/2020 1−6/2019 1-6/2020 MEUR +9% +36% 300 7% 249 243 7% 250 230 200 178 42% 150 -7% +6% 100 44% 43 46 40 38 50 0 Proprietary Products Specialty Proprietary Animal Fermion and Specialty Products Products Products Health Contract Manufacturing
Slide 10: Best-selling pharmaceuticals 1−6/2020
Best-selling pharmaceuticals 1−6/2020 Net sales Change vs. . Indication EUR million 1−6/2019 1. Asthma, COPD 61 +17% 2. Parkinson’s disease 53 +20% 3. Acute heart failure 35 +0% 4. Intensive care sedative 34 +1% 5. Animal sedatives 16 -26% 6. Inflammatory pain 12 +1% 7. Divina series Menopausal symp
Slide 11: Proprietary Products
Proprietary Products
Slide 12: Dexdor® showed growth due to COVID-19
Dexdor® showed growth due to COVID-19 Proprietary Products MEUR +17% +322% sales split 1-6/2020 70 +20% 61 60 60 53 25% 22% 52 +0% +1% 50 44 40 35 34 34 34 30 20 14 14% 10 25% 0 14% Easyhaler® Parkinson's Simdax® Dexdor® Others Parkinson's Easyhaler® franchise franchise Dexdor® Simdax® 1−6/2020 1−6/
Slide 13: Easyhaler® sales +17%
Easyhaler® sales +17% 1-6/2020 Budesonide-formoterol Easyhaler® MEUR 37 (31) +21% 40 1-6/2020 Other Easyhaler® products MEUR 24 (22) +11% 30 Sales, MEUR 20 10 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2015 2016 2017 2018 2019 2020 Other Budesonide-formoterol Easyhaler® Half
Slide 14: Parkinson's franchise sales +20%
Parkinson’s franchise sales +20% 1-6/2020 Own sales MEUR 24 (21) +18% 50 45 1-6/2020 Deliveries to partners MEUR 28 (23) +23% 40 35 Sales, MEUR 30 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2015 2016 2017 2018 2019 2020 Orion own sales Deliveries to partners Ha
Slide 15: Dexdor® and Simdax®
Dexdor® and Simdax® 1-6/2020 Dexdor® MEUR 34 (34) +1 % 1-6/2020 Simdax® MEUR 35 (34) +0 % 20 20 15 15 10 10 5 5 0 0 2015 2016 2017 2018 2019 2020 2015 2016 2017 2018 2019 2020 Half Year Financial Report 1-6/2020 © Orion Corporation 17 July 2020 15
Slide 16: Specialty Products
Specialty Products
Slide 17: Specialty Products: COVID-19 related demand spike levelled off
Specialty Products: COVID-19 related demand spike levelled off Development of net sales Net sales by region Net sales by products 1−6/2020 1−6/2020 MEUR +6% 3% 160 14% 139 140 131 25% 120 13% 100 -3% +10% 80 56% 60 42 44 34 31 17% 40 72% 20 0 Finland Scandinavia Eastern Finland Generic drugs Europe
Slide 18: In Finland, market for reference priced prescription drugs started to level off
In Finland, market for reference priced prescription drugs started to level off after demand spike in March The market for reference priced The sales of Orion's reference prescription drugs in Finland priced prescription drugs (1−6/2020) in Finland MEUR 219 (217) MEUR 55 (55) Market development Orio
Slide 19: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−6/2020 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 1,420 million prescription Orion market share in MEUR drugs pharmacy 180 Orion market share in 25% 160 154 ph
Slide 20: Research and development
Research and development
Slide 21: Orion's key clinical drug development projects
Orion's key clinical drug development projects Project Indication Phase Registration Easyhaler® tiotropium COPD Bioequivalence study Darolutamide 1) Prostate cancer (mHSPC) I II III ODM-109 (oral levosimendan) ALS I II III ODM-203 (targeted FGFR+VEGFR Solid tumours I II inhibitor) 2) ODM-207 (BET pr
Slide 22: Orion's key business targets in 2020
Orion's key business targets in 2020 Commercialisation of darolutamide in • First commercial sales of Europe. ARASENS trial (metastatic prostate darolutamide in Japan and the EU. 1. cancer) continues in order to expand the • Fully recruited ARASENS trial indication for the molecule. estimated to com
Slide 23: Orion's key business targets in 2020
Orion's key business targets in 2020 • Orion is a clear market leader Strengthening Orion’s position as the most both in self-care products and significant provider of generic drugs in reference priced prescription 3. Finland. Competitive product portfolio in drugs in Finland. In self-care Specialty
Slide 24: Patient safety and reliable supply of medications are priorities during COVID-19
Patient safety and reliable supply of medications are priorities also during COVID-19 pandemic MATERIAL THEMES OF SUSTAINABILITY Ensuring patient safety and reliable supply of Responsibility for employees, the environment medications and the ethics and transparency of operations • Ensuring reliable
Slide 25: Corporate responsibility – targets and performance in 2019
Corporate responsibility – targets and performance in 2019 CORPORATE RESPONSIBILITY 2019 FOCUS AREA TARGET PERFORMANCE Patient safety and Ensuring availability of pharmaceutical products ensuring reliable supply of medications Ensuring patient safety Improving energy efficiency Environment Reducing
Slide 26: Outlook
Outlook
Slide 27: Outlook for 2020 (provided on 8 July 2020)
Outlook for 2020 (provided on 8 July 2020) Net sales Orion estimates that in 2020 net sales will be at a similar level as in 2019 (net sales in 2019 were EUR 1,051 million). Operating profit Operating profit is estimated to be slightly higher or higher than in 2019 (in 2019 operating profit was EUR
Slide 28: Orion calendar
Orion calendar Interim Report 1-9/2020 21/10/2020 Financial Statement Release for 2020 9/2/2021 AGM planned to be held 25/3/2021 Interim Report 1-3/2021 27/4/2021 Half-Year Financial Report 19/7/2021 Interim Report 1-9/2021 20/10/2021
Slide 29: Building well-being
Building well-being